Cocrystal Pharma (FRA:8CC) Insider Ownership: 0.00 % (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8CC Cocrystal Pharma Inc FRA:8CC
19 GF Score
Price €0.94
! 4 Warning Signs
View Full Analysis

What is Cocrystal Pharma Insider Ownership?

Cocrystal Pharma FRA:8CC -3.09% 19 Insider Ownership is 0.00 % as of Sep. 05, 2026. GuruFocus rates FRA:8CC with a GF Score™ of 19/100. The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cocrystal Pharma's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cocrystal Pharma's Institutional Ownership is 2.50%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cocrystal Pharma's Float Percentage Of Total Shares Outstanding is 82.12%.

Cocrystal Pharma Insider Ownership Historical Data

* Premium members only.

The historical data trend for Cocrystal Pharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cocrystal Pharma Insider Ownership Chart

Cocrystal Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cocrystal Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:8CC
19GF Score
Cocrystal Pharma Inc FRA:8CC
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cocrystal Pharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Cocrystal Pharma (FRA:8CC) has a Insider Ownership of 0.00 % as of Sep. 05, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Cocrystal Pharma and its competitors.
Is Cocrystal Pharma's Insider Ownership too high?
Cocrystal Pharma's current Insider Ownership is 0.00 %. Overall, Cocrystal Pharma has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Cocrystal Pharma's Insider Ownership compare to AKTX and LGVN?
Cocrystal Pharma's Insider Ownership of 0.00 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Cocrystal Pharma and its competitors. Cocrystal Pharma's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cocrystal Pharma stock overvalued right now?
Cocrystal Pharma (FRA:8CC) has a current Insider Ownership of 0.00 %. The current Insider Ownership is 0.00 %. Cocrystal Pharma's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Cocrystal Pharma (FRA:8CC), the current Insider Ownership is 0.00 % as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cocrystal Pharma Business Description

Other Exchanges COCP:USA
Address 19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
19GF Score

Get the complete analysis for FRA:8CC

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.94
Price